# US 2019/0169197 A1 · Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169197 A1
- Document ID: US20190169197A1
- Status: Published application
- Kind: A1
- Application number: 16/246,181
- Filed: 2019-01-11
- Published: 2019-06-06
- Earliest claimed: 2007-07-12
- Assignees: ChemoCentryx, Inc.
- Applicants: ChemoCentryx, Inc.
- Inventors: Antoni Krasinski; Sreenivas Punna; Solomon Ungashe; Qiang Wang; Yibin Zeng
- Web page: https://patentgrep.com/patent/US20190169197A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 31/06: for tuberculosis
- C07D 213/79: Acids; Esters
- C07D 213/81: Amides; Imides
- C07D 213/84: Nitriles
- C07D 471/04: Ortho-condensed systems
- C07D 471/12: in which the condensed system contains three hetero rings
- C07D 473/00: Heterocyclic compounds containing purine ring systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases and as controls in assays for the identification of CCR2 antagonists.

## Claims

### Claim 1

A compound of the formula (I) or a salt thereof:
wherein
R1 and R2 are each independently hydrogen, halogen, C1-8 alkyl, —CN, or C1-8 haloalkyl, provided that at least one of R1 or R2 is other than hydrogen;
each R3 is independently hydrogen, halogen, or C1-4 alkyl;
R4 is hydrogen or C1-8 alkyl;
R5 is hydrogen, halogen, or C1-8 alkyl optionally substituted with methoxy;
R6 is hydrogen or C1-4 alkyl;
R11 is selected from the group consisting of hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5-to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocycle;
X1 is CR7, N, or NO;
X2 and X4 are each independently N or NO;
X3 is CR7;
X6 and X7 are each independently selected from CR7, N, and NO;
each R7 is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, —CN, —NO2, —OR8, —OC(O)R8, —CO2R8, —C(O)R8, —C(O)NR9R8, —OC(O)NR9R8, —NR10C(O)R8, —NR10C(O)NR9R8, —NR9R8, —NR10CO2R8, —SR8, —S(O)R8, —S(O)2R8, —S(O)2NR9R8, —NR10S(O)2R8, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl and substituted or unsubstituted 3- to 10-membered heterocyclyl;
each occurrence of R8, R9, and R10 is independently selected from the group consisting of hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, aryl, or heteroaryl; or R8 and R9 or R8 and R10, together with the atom(s) to which they are attached, form an substituted or unsubstituted 5-, 6-, or 7-membered ring.

### Claim 2 (depends on 1)

The compound or salt of claim 1, wherein X6 and X7 are each independently selected from CR7.

### Claim 3 (depends on 1)

The compound or salt of claim 1, wherein X1 is N; and X2 and X4 are each N.

### Claim 4

A compound of the formula (II) or a salt thereof:
wherein
R1 and R2 are each independently hydrogen, halogen, substituted or unsubstituted C1-8 alkyl, —CN, or C1-8 haloalkyl, provided that at least one of R1 or R2 is other than hydrogen;
R4 is hydrogen;
R5 is halogen or C1-8 alkyl;
R11 is selected from the group consisting of hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5-to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocycle.

### Claim 5 (depends on 1)

The compound or salt of claim 1, wherein R1 is Cl.

### Claim 6 (depends on 5)

The compound or salt of claim 5, wherein R2 is —CF3.

### Claim 7 (depends on 6)

The compound or salt of claim 6, wherein R5 is Cl or methyl.

### Claim 8 (depends on 7)

The compound or salt of claim 7, wherein R5 is methyl.

### Claim 9 (depends on 1)

The compound or salt of claim 1, wherein R1 is Cl, R2 is CF3, and R5 is Cl.

### Claim 10 (depends on 1)

The compound or salt of claim 1, wherein R11 is hydrogen.

### Claim 11 (depends on 1)

The compound or salt of claim 1, wherein R1 is halogen and R2 is C1-8 haloalkyl.

### Claim 12 (depends on 1)

The compound or salt of claim 1, wherein the compound is selected from the group consisting of:

### Claim 13

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

A composition comprising a pharmaceutically acceptable carrier and a compound or salt of claim 1.

### Claim 15 (depends on 4)

A composition comprising a pharmaceutically acceptable carrier and a compound or salt of claim 4.

### Claim 16 (depends on 13)

A composition comprising a pharmaceutically acceptable carrier and a compound or salt of claim 13.

### Claim 17 (depends on 1)

A method of modulating CCR2 function in a cell in vitro, comprising contacting the cell with a CCR2 modulating amount of the compound or salt of claim 1.

### Claim 18 (depends on 12)

A method of modulating CCR2 function in a cell in vitro, comprising contacting the cell with a CCR2 modulating amount of the compound or salt of claim 12.

### Claim 19 (depends on 13)

A method of treating a CCR2-mediated condition or disease, comprising administering to a subject a therapeutically effective amount of a compound of claim 13, wherein the CCR2-mediated condition or disease is selected from atherosclerosis, restenosis, renal fibrosis, type 2 diabetes, cancer, inflammatory bowel disease, multiple sclerosis, noninsulin-dependent diabetes, pulmonary fibrosis, transplantation rejection, graft-versus-host disease, psoriasis, atopic dermatitis, and asthma.

### Claim 20 (depends on 13)

A method of treating a CCR2-mediated condition or disease, comprising administering to a subject a therapeutically effective amount of a compound of claim 13, wherein the CCR2-mediated condition or disease is selected from transplantation rejection and graft-versus-host disease.
